DTIL · Precision Biosciences Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.84M | - | $13.0K | $18.0K | $29.0K | - | $576.0K | $49.90M | $17.58M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $13.11M | - | $13.35M | $12.77M | $13.59M | - | $13.08M | $17.23M | $13.34M | - |
| SG&A | $6.80M | - | $7.33M | $9.13M | $8.55M | - | $8.77M | $8.53M | $8.43M | - |
| Total Operating Expenses | $19.91M | - | $20.68M | $21.89M | $22.14M | - | $21.85M | $25.75M | $21.77M | - |
| D&A | $299.0K | - | - | - | $395.0K | - | - | - | $1.14M | - |
| Operating Income | ($9.07M) | - | ($20.67M) | ($21.88M) | ($22.11M) | - | ($21.27M) | $24.15M | ($4.19M) | - |
| Interest Expense | $311.0K | - | $256.0K | $560.0K | $354.0K | - | $256.0K | $560.0K | $574.0K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($18.44M) | - | ($21.77M) | ($23.52M) | ($20.57M) | - | ($16.43M) | $32.75M | $8.59M | - |
| EPS - Basic | ($0.75) | - | ($1.84) | ($2.13) | ($2.21) | - | ($2.25) | $4.70 | $1.70 | - |
| EPS - Diluted | ($0.75) | - | ($1.84) | ($2.13) | ($2.21) | - | ($2.25) | $4.67 | $1.70 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $99.37M | $110.82M | $44.87M | $62.24M | $77.22M | $85.90M | $98.75M | $123.57M | $137.77M | $116.68M |
| Accounts Receivable | $4.00M | $0 | $4.0K | $0 | $4.0K | $229.0K | $188.0K | $207.0K | $390.0K | $901.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $944.0K | $296.0K | $1.34M | $1.12M | $924.0K | $1.31M | $958.0K | $1.14M | $1.14M | $2.97M |
| Current Assets | $108.69M | $118.74M | $51.70M | $70.26M | $82.10M | $94.99M | $110.52M | $144.03M | $160.83M | $136.36M |
| Total Assets | $143.89M | $154.42M | $93.51M | $108.93M | $124.41M | $136.39M | $153.26M | $165.80M | $184.74M | $159.78M |
| Current Liabilities | $7.75M | $8.91M | $15.00M | $13.57M | $12.39M | $14.98M | $11.98M | $32.96M | $33.34M | $49.99M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $67.79M | $62.17M | $76.88M | $74.87M | $75.07M | $80.00M | $88.39M | $91.09M | $147.53M | $140.92M |
| Stockholders' Equity | $76.10M | $92.25M | $16.63M | $34.05M | $49.34M | $56.39M | $64.87M | $74.71M | $37.21M | $18.86M |
| Retained Earnings | ($546.63M) | ($528.19M) | ($548.32M) | ($526.55M) | ($503.03M) | ($482.46M) | ($464.72M) | ($448.29M) | ($481.04M) | ($489.63M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($11.94M) | - | - | - | ($19.05M) | - | - | - | ($18.98M) | - |
| Investing Cash Flow | ($114.0K) | - | - | - | ($314.0K) | - | - | - | ($26.0K) | - |
| Financing Cash Flow | $745.0K | - | - | - | $10.69M | - | - | - | $40.09M | - |
| CapEx | $18.0K | - | - | - | $64.0K | - | - | - | $86.0K | - |
| Free Cash Flow | ($11.96M) | - | - | - | ($19.12M) | - | - | - | ($19.07M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -83.7% | - | -158976.9% | -121538.9% | -76248.3% | - | -3693.6% | 48.4% | -23.8% | - |
| EBITDA margin | -81.0% | - | - | - | -74886.2% | - | - | - | -17.3% | - |
| Net margin | -170.2% | - | -167476.9% | -130666.7% | -70913.8% | - | -2851.6% | 65.6% | 48.8% | - |
| Free cash flow margin | -110.3% | - | - | - | -65917.2% | - | - | - | -108.4% | - |
| FCF / Net income | 0.65 | - | - | - | 0.93 | - | - | - | -2.22 | - |
| R&D / Revenue | 121.0% | - | 102707.7% | 70933.3% | 46855.2% | - | 2271.5% | 34.5% | 75.9% | - |
| SG&A / Revenue | 62.8% | - | 56369.2% | 50705.6% | 29493.1% | - | 1522.0% | 17.1% | 47.9% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -12.8% | - | -23.3% | -21.6% | -16.5% | - | -10.7% | 19.8% | 4.6% | - |
| Return on equity | -24.2% | - | -130.9% | -69.1% | -41.7% | - | -25.3% | 43.8% | 23.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 14.02 | 13.32 | 3.45 | 5.18 | 6.62 | 6.34 | 9.22 | 4.37 | 4.82 | 2.73 |
| Quick ratio | 14.02 | 13.32 | 3.45 | 5.18 | 6.62 | 6.34 | 9.22 | 4.37 | 4.82 | 2.73 |
| Cash ratio | 12.81 | 12.43 | 2.99 | 4.59 | 6.23 | 5.73 | 8.24 | 3.75 | 4.13 | 2.33 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -29.2x | - | -80.7x | -39.1x | -62.5x | - | -83.1x | 43.1x | -7.3x | - |
| Equity multiplier | 1.89 | 1.67 | 5.62 | 3.20 | 2.52 | 2.42 | 2.36 | 2.22 | 4.97 | 8.47 |
| Liabilities / Assets | 0.47 | 0.40 | 0.82 | 0.69 | 0.60 | 0.59 | 0.58 | 0.55 | 0.80 | 0.88 |
| Efficiency | ||||||||||
| Asset turnover | 0.08 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.30 | 0.10 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 135d | - | 112d | 0d | 50d | - | 119d | 2d | 8d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | 2.1x | 8.0x | - |
| P / B | 1.8x | - | 3.9x | 1.4x | 0.9x | - | 1.0x | 0.9x | 1.8x | - |
| P / S | 12.5x | - | 5018.2x | 2577.5x | 1528.4x | - | 113.4x | 1.4x | 3.9x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 37272.4% | - | -97.7% | -100.0% | -99.8% | - | -95.6% | 152.2% | 100.3% | - |
| Revenue CAGR (3y) | 7.3% | - | -87.9% | -83.2% | -79.4% | - | -71.2% | -10.2% | 2.5% | - |
| Revenue CAGR (5y) | -7.9% | - | -71.9% | -55.9% | -66.6% | - | -25.7% | 56.1% | 26.3% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 59.0% | - | 2.9% | - | -428.1% | - | -72.1% | - | 82.9% | - |
| Net income growth (YoY) | 10.3% | - | -32.6% | - | - | - | -103.3% | - | - | - |
| EPS growth (YoY) | 66.1% | - | 18.2% | - | - | - | -3114.3% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 37.5% | - | - | - | -0.3% | - | - | - | 40.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 54.2% | 63.6% | -74.4% | -54.4% | 32.6% | 199.0% | 123.2% | 119.5% | -7.4% | -68.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$34.26M totalOperating Segment$34.26M · 100.0%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing PRECISION BIOSCIENCES INC against the 5 most active filers in the same SIC group.